 FREMONT, Calif., Feb. 22, 2021 GLOBE NEWSWIRE -- Zosano Pharma Corporation NASDAQ:ZSAN, a clinical-stage biopharmaceutical company, today announced that the company has received the official Type A meeting minutes from the U.S. Food and Drug Administration FDA Division of Neurology II the Division regarding the requirements for resubmission of the QtryptaTM zolmitriptan transdermal microneedle system 505b2 New Drug Application NDA following the Complete Response Letter received on October 20, 2020. 